Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2

0555182 - BC 2022 RIV CH eng J - Článek v odborném periodiku
Tonk, M. - Růžek, Daniel - Vilcinskas, A.
Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2.
Viruses. Roč. 13, č. 5 (2021), č. článku 912. E-ISSN 1999-4915
Institucionální podpora: RVO:60077344
Klíčová slova: virus * inhibition * defensin * mice * SARS-CoV-2 * covid-19 * coronavirus * antimicrobial peptides * antiviral peptides * defensins
Obor OECD: Virology
Impakt faktor: 5.818, rok: 2021
Způsob publikování: Open access
https://www.mdpi.com/1999-4915/13/5/912

Multiple outbreaks of epidemic and pandemic viral diseases have occurred in the last 20 years, including those caused by Ebola virus, Zika virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence or re-emergence of such diseases has revealed the deficiency in our pipeline for the discovery and development of antiviral drugs. One promising solution is the extensive library of antimicrobial peptides (AMPs) produced by all eukaryotic organisms. AMPs are widely known for their activity against bacteria, but many possess additional antifungal, antiparasitic, insecticidal, anticancer, or antiviral activities. AMPs could therefore be suitable as leads for the development of new peptide-based antiviral drugs. Sixty therapeutic peptides had been approved by the end of 2018, with at least another 150 in preclinical or clinical development. Peptides undergoing clinical trials include analogs, mimetics, and natural AMPs. The advantages of AMPs include novel mechanisms of action that hinder the evolution of resistance, low molecular weight, low toxicity toward human cells but high specificity and efficacy, the latter enhanced by the optimization of AMP sequences. In this opinion article, we summarize the evidence supporting the efficacy of antiviral AMPs and discuss their potential to treat emerging viral diseases including COVID-19.
Trvalý link: http://hdl.handle.net/11104/0329709